Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

NCT04642469 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non- Small Cell Lung

Interventions

DRUG: Durvalumab
OTHER: Placebo

Sponsor

AstraZeneca